Bio Pharma Dive
MARCH 20, 2024
The company claims its approach could yield more effective and safer T-cell engagers, a type of cancer medicine that’s attracted significant interest from drugmakers in recent years.
Pharmaceutical Technology
MARCH 20, 2024
Johnson & Johnson has received approval from the FDA for EDURANT PED to treat human immunodeficiency virus-1 (HIV-1) in children.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
MARCH 20, 2024
Orchard is counting on the long-term data it’s accrued to convince insurers to cover Lenmeldy’s $4.25 million list price, the highest of any genetic medicine to come to market.
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 20, 2024
Brain scans of a 72-year-old man diagnosed with a highly aggressive form of cancer known as a glioblastoma have revealed a remarkable regression in his tumor’s size within days of receiving an infusion of an innovative new treatment.
Bio Pharma Dive
MARCH 20, 2024
The biotech, which raised $540 million in an initial public offering last year, is pitching the medicine as a potential challenger to Amgen’s blockbuster eye drug Tepezza.
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 20, 2024
Rustom Lawyer, co-founder & CEO of Augnito, a leading voice AI solutions provider, has unveiled profound insights into the potential of voice artificial intelligence (AI) in healthcare. Emphasizing its transformative role, Lawyer shed light on how voice AI is reshaping the landscape of healthcare, empowering a new generation of healthcare professionals – the ‘superclinicians.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Rethinking Clinical Trials
MARCH 20, 2024
Dr. Warren Jones In this Friday’s PCT Grand Rounds, Warren Jones of Emory University will present “Early Diagnosis and Assessment of Autism via Objective Measurements of Social Visual Engagement.” The Grand Rounds session will be held on Friday, March 22, 2024, at 1:00 pm eastern. Jones is the director of research at the Marcus Autism Center and the Norman Nien Distinguished Chair in Autism and an associate professor of pediatrics at the Emory University School of Medicine.
Pharmaceutical Technology
MARCH 20, 2024
The US Food and Drug Administration (FDA) has granted approval for Boehringer Ingelheim's SPEVIGO injection to treat generalised pustular psoriasis (GPP).
Worldwide Clinical Trials
MARCH 20, 2024
In the increasingly advancing world of medicine, personalized care is a key factor that can progress your drug development efforts. One way to ensure customized disease management is to utilize pharmacogenomics (PGx) in your clinical trial. As the study of how an individual’s genes affect their response to drugs, pharmacogenomics is a critical factor in developing effective and safe drugs and dosages in clinical trials. 6 Ways Pharmacogenomics Helps Your Clinical Trial Enhances Drug Safety PGx a
Pharmaceutical Technology
MARCH 20, 2024
GlobalData tracks 22 drugs in development for Inherited Mitochondrial Disorders by 19 companies/universities/institutes. The top development phase for Inherited Mitochondrial Disorders is preclinical, with 13 drugs in that stage.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioSpace
MARCH 20, 2024
As part of a sweeping reorganization, Bayer Pharmaceuticals on Wednesday shuffled its leadership roster, which included the creation of a new unit and role changes for its executives.
Pharmaceutical Technology
MARCH 20, 2024
GlobalData tracks 59 drugs in development for Conjunctivitis by 51 companies/universities/institutes. The top development phase for Conjunctivitis is preclinical, with 20 drugs in that stage.
Fierce Pharma
MARCH 20, 2024
Four months ago, when BioNTech slashed its 2023 revenue projection from 5 billi | When BioNTech reported its fourth-quarter earnings Wednesday, it was another harsh reminder of the plummeting demand for COVID-19 vaccines. Sales came to 1.5 billion euros ($1.6 billion) for the fourth quarter and 3.8 billion euros ($4.1 billion) for 2023, coming up short of expectations.
Pharmaceutical Technology
MARCH 20, 2024
GlobalData tracks 150 drugs in development for Gastroesophageal (GE) Junction Carcinomas by 115 companies/universities/institutes. The top development phase for Gastroesophageal (GE) Junction Carcinomas is phase ii, with 72 drugs in that stage.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
MARCH 20, 2024
Understanding the employee experience in healthcare is essential for improving the patient experience. Learn more about the importance of employee experience in healthcare and how it impacts patient care.
Pharmaceutical Technology
MARCH 20, 2024
GlobalData tracks 5 drugs in development for Meibomian Blepharitis by six companies/universities/institutes. The top development phase for Meibomian Blepharitis is phase ii, with three drugs in that stage.
Pharma Times
MARCH 20, 2024
Rare kidney diseases are a group of conditions which account for over 5% of people living with chronic kidney disease
Pharmaceutical Technology
MARCH 20, 2024
GlobalData tracks 5 drugs in development for Blepharospasm by four companies/universities/institutes. The top development phase for Blepharospasm is phase ii, with two drugs in that stage.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
XTalks
MARCH 20, 2024
In this featured episode of Xtalks People in Life Sciences, Ayesha spoke with Ashish Jain, Senior Director of Clinical Safety and Pharmacovigilance (PV) at Curis , a pioneering biotech company specializing in cutting-edge cancer therapies. Jain shared his journey into clinical safety and PV, highlighting key milestones along the way. Delving into his daily work at Curis, he revealed his strategies for prioritizing tasks and staying informed of the latest developments in PV.
Pharmaceutical Technology
MARCH 20, 2024
GlobalData tracks 76 drugs in development for Retinal Degeneration by 63 companies/universities/institutes. The top development phase for Retinal Degeneration is preclinical, with 40 drugs in that stage.
Fierce Pharma
MARCH 20, 2024
As two of the world’s largest pharmaceutical companies, Johnson & Johnson and Pfizer have long been rivals in various therapeutic areas. | The company is accusing former employee Andrew Brackbill of downloading thousands of confidential strategy-related files before leaving for rival Pfizer.
Pharmaceutical Technology
MARCH 20, 2024
GlobalData tracks 198 drugs in development for Retinopathy by 163 companies/universities/institutes. The top development phase for Retinopathy is preclinical, with 131 drugs in that stage.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
XTalks
MARCH 20, 2024
World Water Day , observed annually on March 22, serves as a poignant reminder of the essential role water plays in our survival, prosperity and the health of our planet. As we approach World Water Day 2024, the theme “Water For Peace” underscores the intrinsic link between water management and conflict prevention. This year’s observance not only highlights the critical importance of water but also urges us to reflect on our relationship with this invaluable resource.
Pharmaceutical Technology
MARCH 20, 2024
GlobalData tracks 46 drugs in development for Lewy Body Dementia by 36 companies/universities/institutes. The top development phase for Lewy Body Dementia is preclinical, with 21 drugs in that stage.
BioSpace
MARCH 20, 2024
Keytruda, when used with AstraZeneca’s Lynparza, did not significantly improve overall and progression-free survival in specific patients with metastatic non-squamous non-small cell lung cancer.
Pharmaceutical Technology
MARCH 20, 2024
GlobalData tracks 5 drugs in development for Choriocarcinoma (Gestational Trophoblastic Neoplasia) by four companies/universities/institutes. The top development phase for Choriocarcinoma (Gestational Trophoblastic Neoplasia) is phase i, with four drugs in that stage.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
BioSpace
MARCH 20, 2024
A new analysis from the Congressional Budget Office predicts that Novo Nordisk’s semaglutide will likely be subjected to Medicare’s Drug Price Negotiation Program under the Inflation Reduction Act.
Pharmaceutical Technology
MARCH 20, 2024
Everest Medicines has received approval from the Singapore Health Sciences Authority (HSA) for NEFEGAN to treat primary immunoglobulin A nephropathy (IgAN) in adults at disease progression risk.
Fierce Pharma
MARCH 20, 2024
After Johnson & Johnson last year changed its mind on its 2017 purchase of ap | Idorsia's Tryvio is the first oral anti-hypertensive therapy that uses a new therapeutic mechanism in nearly 40 years, suggesting the dawn of "a new era of endothelin research," the company said.
Pharmaceutical Technology
MARCH 20, 2024
Cellectis presented promising data with UCART20x22, which represents a pioneering allogeneic dual CAR T-cell product designed to target two established antigens.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
278 
Let's personalize your content